Financhill
Sell
30

AXGN Quote, Financials, Valuation and Earnings

Last price:
$10.96
Seasonality move :
9.01%
Day range:
$10.94 - $11.58
52-week range:
$6.34 - $21.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.60x
P/B ratio:
4.88x
Volume:
580.2K
Avg. volume:
617.7K
1-year change:
80.22%
Market cap:
$514.6M
Revenue:
$187.3M
EPS (TTM):
-$0.15

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AXGN
Axogen
$48.3M $0.02 10.96% -76% $24.43
AHCO
AdaptHealth
$764.8M $0.04 35.28% 19.85% $12.88
ELMD
Electromed
$15.8M -- 12.26% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 21.89% -258.33% $9.05
STXS
Stereotaxis
$6.9M -$0.07 72.15% -3.57% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AXGN
Axogen
$11.30 $24.43 $514.6M -- $0.00 0% 2.60x
AHCO
AdaptHealth
$9.31 $12.88 $1.3B 16.33x $0.00 0% 0.39x
ELMD
Electromed
$20.32 $37.00 $170.4M 25.72x $0.00 0% 2.97x
IRIX
IRIDEX
$0.94 -- $15.8M -- $0.00 0% 0.32x
MYO
Myomo
$3.14 $9.05 $113M -- $0.00 0% 3.16x
STXS
Stereotaxis
$2.13 $4.50 $183.2M -- $0.00 0% 6.68x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AXGN
Axogen
31.17% 1.036 5.67% 2.22x
AHCO
AdaptHealth
55.53% 0.843 133.26% 0.82x
ELMD
Electromed
-- 2.545 -- 4.79x
IRIX
IRIDEX
81.05% 1.797 21.92% 1.11x
MYO
Myomo
-- 2.360 -- 2.24x
STXS
Stereotaxis
-- 1.450 -- 0.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AXGN
Axogen
$34.9M -$1.7M -4.88% -7.2% -3.26% -$13.8M
AHCO
AdaptHealth
-$77M $23.2M 2.39% 5.59% 3.99% -$58K
ELMD
Electromed
$12.2M $2.1M 16.57% 16.57% 13.65% $2.2M
IRIX
IRIDEX
$5.1M -$205K -140.14% -218.69% -1.72% -$1.2M
MYO
Myomo
$6.6M -$3.5M -38.11% -38.11% -35.81% -$3.3M
STXS
Stereotaxis
$4.1M -$5.9M -174.6% -174.6% -79.35% -$1.8M

Axogen vs. Competitors

  • Which has Higher Returns AXGN or AHCO?

    AdaptHealth has a net margin of -7.9% compared to Axogen's net margin of -1.24%. Axogen's return on equity of -7.2% beat AdaptHealth's return on equity of 5.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
    AHCO
    AdaptHealth
    -13.26% -$0.05 $3.5B
  • What do Analysts Say About AXGN or AHCO?

    Axogen has a consensus price target of $24.43, signalling upside risk potential of 116.18%. On the other hand AdaptHealth has an analysts' consensus of $12.88 which suggests that it could grow by 38.29%. Given that Axogen has higher upside potential than AdaptHealth, analysts believe Axogen is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    AHCO
    AdaptHealth
    5 2 0
  • Is AXGN or AHCO More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison AdaptHealth has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.885%.

  • Which is a Better Dividend Stock AXGN or AHCO?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AdaptHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. AdaptHealth pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or AHCO?

    Axogen quarterly revenues are $48.6M, which are smaller than AdaptHealth quarterly revenues of $580.5M. Axogen's net income of -$3.8M is higher than AdaptHealth's net income of -$7.2M. Notably, Axogen's price-to-earnings ratio is -- while AdaptHealth's PE ratio is 16.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.60x versus 0.39x for AdaptHealth. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    2.60x -- $48.6M -$3.8M
    AHCO
    AdaptHealth
    0.39x 16.33x $580.5M -$7.2M
  • Which has Higher Returns AXGN or ELMD?

    Electromed has a net margin of -7.9% compared to Axogen's net margin of 12.06%. Axogen's return on equity of -7.2% beat Electromed's return on equity of 16.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
    ELMD
    Electromed
    77.97% $0.21 $43.9M
  • What do Analysts Say About AXGN or ELMD?

    Axogen has a consensus price target of $24.43, signalling upside risk potential of 116.18%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 82.09%. Given that Axogen has higher upside potential than Electromed, analysts believe Axogen is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    ELMD
    Electromed
    2 0 0
  • Is AXGN or ELMD More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

  • Which is a Better Dividend Stock AXGN or ELMD?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or ELMD?

    Axogen quarterly revenues are $48.6M, which are larger than Electromed quarterly revenues of $15.7M. Axogen's net income of -$3.8M is lower than Electromed's net income of $1.9M. Notably, Axogen's price-to-earnings ratio is -- while Electromed's PE ratio is 25.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.60x versus 2.97x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    2.60x -- $48.6M -$3.8M
    ELMD
    Electromed
    2.97x 25.72x $15.7M $1.9M
  • Which has Higher Returns AXGN or IRIX?

    IRIDEX has a net margin of -7.9% compared to Axogen's net margin of -14.17%. Axogen's return on equity of -7.2% beat IRIDEX's return on equity of -218.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
    IRIX
    IRIDEX
    42.49% -$0.10 $4.5M
  • What do Analysts Say About AXGN or IRIX?

    Axogen has a consensus price target of $24.43, signalling upside risk potential of 116.18%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 112.09%. Given that Axogen has higher upside potential than IRIDEX, analysts believe Axogen is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is AXGN or IRIX More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

  • Which is a Better Dividend Stock AXGN or IRIX?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or IRIX?

    Axogen quarterly revenues are $48.6M, which are larger than IRIDEX quarterly revenues of $11.9M. Axogen's net income of -$3.8M is lower than IRIDEX's net income of -$1.7M. Notably, Axogen's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.60x versus 0.32x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    2.60x -- $48.6M -$3.8M
    IRIX
    IRIDEX
    0.32x -- $11.9M -$1.7M
  • Which has Higher Returns AXGN or MYO?

    Myomo has a net margin of -7.9% compared to Axogen's net margin of -35.24%. Axogen's return on equity of -7.2% beat Myomo's return on equity of -38.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
    MYO
    Myomo
    67.23% -$0.08 $21.7M
  • What do Analysts Say About AXGN or MYO?

    Axogen has a consensus price target of $24.43, signalling upside risk potential of 116.18%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 188.22%. Given that Myomo has higher upside potential than Axogen, analysts believe Myomo is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    MYO
    Myomo
    3 0 0
  • Is AXGN or MYO More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

  • Which is a Better Dividend Stock AXGN or MYO?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or MYO?

    Axogen quarterly revenues are $48.6M, which are larger than Myomo quarterly revenues of $9.8M. Axogen's net income of -$3.8M is lower than Myomo's net income of -$3.5M. Notably, Axogen's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.60x versus 3.16x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    2.60x -- $48.6M -$3.8M
    MYO
    Myomo
    3.16x -- $9.8M -$3.5M
  • Which has Higher Returns AXGN or STXS?

    Stereotaxis has a net margin of -7.9% compared to Axogen's net margin of -77.93%. Axogen's return on equity of -7.2% beat Stereotaxis's return on equity of -174.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
    STXS
    Stereotaxis
    54.39% -$0.07 $8.2M
  • What do Analysts Say About AXGN or STXS?

    Axogen has a consensus price target of $24.43, signalling upside risk potential of 116.18%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 111.27%. Given that Axogen has higher upside potential than Stereotaxis, analysts believe Axogen is more attractive than Stereotaxis.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    STXS
    Stereotaxis
    2 0 0
  • Is AXGN or STXS More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

  • Which is a Better Dividend Stock AXGN or STXS?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or STXS?

    Axogen quarterly revenues are $48.6M, which are larger than Stereotaxis quarterly revenues of $7.5M. Axogen's net income of -$3.8M is higher than Stereotaxis's net income of -$5.8M. Notably, Axogen's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.60x versus 6.68x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    2.60x -- $48.6M -$3.8M
    STXS
    Stereotaxis
    6.68x -- $7.5M -$5.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

Buy
88
SMR alert for May 28

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock